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Abstract
The mechanisms of chronic HBV infection and immunopathogenesis are poorly understood due to a lack of a robust small
animal model. Here we report the development of a humanized mouse model with both human immune system and
human liver cells by reconstituting the immunodeficient A2/NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice with human HLA-A2
transgene) with human hematopoietic stem cells and liver progenitor cells (A2/NSG-hu HSC/Hep mice). The A2/NSG-hu
HSC/Hep mouse supported HBV infection and approximately 75% of HBV infected mice established persistent infection for
at least 4 months. We detected human immune responses, albeit impaired in the liver, chronic liver inflammation and liver
fibrosis in infected animals. An HBV neutralizing antibody efficiently inhibited HBV infection and associated liver diseases in
humanized mice. In addition, we found that the HBV mediated liver disease was associated with high level of infiltrated
human macrophages with M2-like activation phenotype. Importantly, similar M2-like macrophage accumulation was
confirmed in chronic hepatitis B patients with liver diseases. Furthermore, gene expression analysis showed that induction
of M2-like macrophage in the liver is associated with accelerated liver fibrosis and necrosis in patients with acute HBV-
induced liver failure. Lastly, we demonstrate that HBV promotes M2-like activation in both M1 and M2 macrophages in cell
culture studies. Our study demonstrates that the A2/NSG-hu HSC/Hep mouse model is valuable in studying HBV infection,
human immune responses and associated liver diseases. Furthermore, results from this study suggest a critical role for
macrophage polarization in hepatitis B virus-induced immune impairment and liver pathology.
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Introduction
Chronic hepatitis B virus (HBV) infection results in liver
fibrosis/cirrhosis and development of hepatocellular carcinoma
(HCC) [1,2]. Establishment of chronic HBV infection is inversely
associated with patient’s age with neonatal and infants most
susceptible, while adults are mostly resistant to chronic infection
[3,4]. Chronic HBV infection is associated with impaired immune
responses to viral antigens and chronic inflammation in the liver,
leading to progressive liver diseases. Though HBV-induced liver
disease is predominately a chronic disease, requiring decades of
chronic infection and liver inflammation [5,6,7], HBV infection
occasionally results in accelerated liver disease and liver failure
during acute infection [8,9]. The development of preventive
vaccines and therapeutics using chimpanzees and surrogate
hepatitis virus-small animal models has played a significant role
in preventing new infections and controlling HBV-induced liver
diseases. However, HBV is endemic in many developing countries
with over 350 million people worldwide chronically infected [10].
Delineation of the mechanisms by which HBV evades host
immunity to establish chronic infection and promote liver disease
is hampered by the lack of robust animal models [11,12,13].
HBV and other human hepatotropic pathogens including HCV
have host species restriction, namely humans and chimpanzees.
To overcome host species restriction barrier for in vivo infection
and disease modeling, several human-murine chimeric liver
models have been developed [14]. The Alb-uPA/SCID human-
ized mouse with high human adult hepatocyte repopulation can be
infected with HCV/HBV [14]. Additionally, the fumarylacetoa-
cetate hydrolase (Fah)-Rag2-cC-null mice also allow human
hepatocytes engraftment and HCV infection [15,16,17]. However,
these human-murine chimeric liver models lack a functional
human immune system, thus it is not possible to study host
immune response and hepatitis virus-induced immunopathology
[14,17]. To overcome the limitations associated with current
chimeric human-murine liver mouse models, we have recently
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developed a humanized mouse model with both human immune
system and liver cells (AFC8-hu HSC/Hep mice) [18,19]. AFC8-
hu HSC/Hep mice can support HCV infection in the liver and
generate human T-cell response to HCV. Additionally, HCV
infection induces liver inflammation and fibrosis, correlated with
activation of human hepatic stellate cells and expression of human
fibrogenic genes [18].
Chronic liver inflammation and associated pathology in chronic
HBV infection is characterized by infiltration of various leukocyte
populations including activated macrophages. Several reports
suggest that HBV promotes macrophage activation and M2
polarization [20,21,22]. Macrophages play a critical role in
modulating pathogen clearance, chronic inflammation and
associated liver pathology; with M1 polarized macrophages
promoting pathogen clearance, and M2-like polarized macro-
phages impairing host immunity and promoting tissue fibrosis/
remodeling [23,24,25,26,27].
In this study, we developed a humanized mouse model by
injecting human liver progenitor cells (Hep) and CD34+ human
hematopoietic stem cells (HSC) directly into the liver of newborn
A2/NSG (HLA-A2 transgenic NOD scid IL2 receptor gamma
chain knockout mice [28,29,30]). The A2/NSG mouse lacks NK
cells and T/B-lymphocytes. They support efficient development
of a functional human immune system after injecting CD34+
human hematopoietic stem cells (HSC) into the liver of newborn
mice [30,31]. Furthermore, the A2/NSG mouse carries the
human HLA-A2 transgene, which enhances development of
human MHC-restrict T lymphocytes [30]. To promote human
liver cell repopulation, A2/NSG-hu HSC/Hep mice were treated
with a murine specific anti-Fas agonistic antibody (Jo2)
[32,33,34,35,36]. The A2/NSG-hu HSC/Hep mouse model
enabled human liver and immune system development and
supported long-term HBV infection, anti-HBV human immune
response and HBV-induced liver diseases including hepatitis and
fibrosis. Interestingly, we also observed accumulation of activated
human M2-like macrophages in the HBV-infected humanized
liver. Importantly, similar M2-like macrophage accumulation was
confirmed in chronic HBV patients and HBV-induced acute liver
failure patients. Importantly, inoculation of human macrophages
culture with HBV positive supernatant resulted in M2–like
activation.
Results
The A2/NSG-hu HSC/Hep mouse model supports
persistent HBV infection
We utilized the murine Fas activating antibody (Jo2
antibody) to induce murine-specific hepatocytes death in order
to promote human hepatocytes repopulation. We confirmed
the specie-specificity of Jo2 antibody [32] by incubating human
liver cell line (HepG2) with Jo2 antibody. Jo2 antibody did not
stain the human hCD95+ hepatocyte cell line (Figure S1A).
Furthermore, human fetal liver progenitor cells were resistant
to Jo2 antibody - mediated apoptosis, while A2/NSG mice
were susceptible to Jo2 - induced liver damage (Figure S1B,
S1C). Jo2 antibody treatment of mice transplanted with CD34+
HSCs and liver progenitor cells resulted in a significant
increase in Hep Par1 positive human hepatocytes compared
to vehicle treated animals at approximately 3 months post
transplantation (Figure 1A, 1B). No significant liver disease was
observed in Jo2 antibody treated animals at termination, thus
confirming that low dose Jo2 mediated liver damage is
transient and does not induce long-term liver damage
(Figure 1A). Human serum Albumin levels were significantly
elevated in Jo2 antibody treated transplanted animals com-
pared to vehicle treated animals at 3 months post transplan-
tation (Figure 1C). Additionally, Jo2 antibody treated A2/NSG
animals transplanted with CD34+ HSCs and liver progenitor
cells supported robust human immune cells repopulation
(,75% PBMCs are human CD45+), which was comparable
to A2/NSG animals transplanted with HSCs only and not
treated with Jo2 (Figure 1D). Human immune reconstitution
resulted in the repopulation of blood, lymphoid tissues and
liver with human leukocytes (hCD45+) including T cells
(hCD45+ hCD3+), B cells (hCD45+ hCD19+), monocytes/
macrophages (hCD45+ hCD32 hCD192 hCD562
hHLADR+ hCD14high hCD11chigh), myeloid dendritic cells
(hCD45+ hCD32 hCD192 hCD562 hHLADR+ hCD14low
hCD11chigh) and plasmacytoid dendritic cells (hCD45+
hCD32 hCD192 hCD562 hHLADR+ hCD123high
hCD4high) (Figure 1E, Figure S2).
To determine if the A2/NSG-hu HSC/Hep mouse can
support HBV infection, humanized and non-humanized mice
were inoculated with HBV patient isolates at 1610e3, 10e5 or
10e7 genome copies per mouse (Figure 2A). HBV viral infection
was examined by measuring serum levels of HBV genome and
HBsAg. At 10e5 HBV genome copies/mouse, HBV replication
was detected at 4 weeks post-infection (wpi), whereas low levels of
HBV genomes were detected at 2 wpi (10e4 copies/ml) and
reached higher levels at 4 wpi (4610e5 copies/ml) in mice
inoculated at 10e7 HBV/mouse (Fig. 2A). Serum HBs antigen
was persistently detected in approximately 75% of HBV
inoculated humanized mice (HBV), but not in non-transplanted
control mice inoculated with HBV (NTP-HBV) or mock
inoculated humanized mice (Mock) (Figure 2B, Table S1).
Additionally, serum HBV genome was detected in approximately
75% of HBV inoculated humanized mice but not in HBV
inoculated non-humanized mice or mock inoculated humanized
mice at sacrifice time point (Figure 2C). To examine HBV
infection in the liver, animals were sacrificed at approximately
12–16 weeks post inoculation. HBV core and surface antigens
were detected in the livers of all humanized mice with detectable
Author Summary
Over 350 million people worldwide are chronically infected
with the hepatitis B virus (HBV), which leads to severe liver
diseases including fibrosis and cancer. The mechanisms of
chronic HBV infection and disease are poorly understood
due to a lack of a robust small animal model. Here we
report a novel animal model that can be efficiently
repopulated with both human immune and liver cells.
The A2/NSG-hu HSC/Hep humanized mouse model sup-
ported persistent HBV infection, human immune respons-
es, albeit impaired in the liver, chronic liver inflammation
and liver fibrosis. In addition, we found that the HBV
mediated liver immune impairment and liver disease was
associated with high level of infiltrated human immuno-
suppressive/pro-fibrogenic macrophages; this result was
confirmed in chronic HBV-induced liver disease patients
and acute HBV – induced liver failure patients. Importantly,
we demonstrate that HBV promotes immuno-suppressive/
pro-fibrogenic macrophage polarization in human macro-
phages using cell culture models. The humanized mouse
model is a valuable platform in studying HBV infection,
human immune response and liver diseases. Furthermore,
results from this study suggest a critical role for macro-
phage activation in hepatitis B induced liver diseases, thus
providing a novel therapeutic target.
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HBV viremia, but not in the livers of control animals (non-
transplanted mice inoculated with HBV and mock inoculated
humanized mice) (Figure 2D, Table S1). Additionally, HBV
genomes were detected in HBV infected A2/NSG/Fas-hu HSC/
Hep livers (Figure S3).
HBV infection induces human immune response in the
A2/NSG/Fas-hu HSC/Hep mouse
To characterize human immune response to HBV infection
in humanized mice, human cytokines, B cell and T cells
responses were examined. Elevated levels of human cytokines
were detected in the serum of HBV infected mice with relatively
high levels of IFNc, IP10 and IL6, along with low levels of IL10
and IFNa (Figure 3A). Additionally, HBV infection also resulted
in anti-HBV humoral response. We detected elevated levels of
anti-HBs IgM antibody in infected humanized mice compared
to control animals (Figure 3B). However, antigen-specific IgG
response was detected in only two of eight mice and at very low
levels as reported in other human B cell studies with humanized
mice [37]. To characterize anti-HBV human T cell immune
response, HLA-A2 donor derived-leukocytes from the spleen
and lymph nodes of mock- or HBV-infected humanized animals
were collected and stimulated in vitro with PHA or A2-restricted
HBV peptides plus anti-CD28 mAb and expanded in the
presence of IL2 and IL7 for 2 weeks. Human T cells from both
mock and HBV infected humanized mice responded to PHA
stimulation, however higher expansion of T cells from HBV
infected mice was detected than T cells from mock controls
(Figure 3C). Analysis of human T cell expansion following HBV
antigen stimulation showed robust expansion (,20 fold) of
human T cells from HBV-infected humanized mice and no
expansion of human T cells from mock controls (Figure 3D).
Additionally, stimulation with the A2-restricted peptides pref-
erentially expanded CD8+ T cells (Figure 3D). A2/HBV
peptide pentamer staining showed significantly higher frequency
of the immunodominant HBV Core peptide (aa18–aa27)
specific human CD8+ T cells (Figure 3E). Similarly as in human
studies, HBV Core (aa18–aa27) pentamer+ CD8+ T cells
exhibited significantly higher frequency than the HBV Env
(aa183–aa191) pentamer+ CD8+ T cells (Figure 3E). As
expected, infiltration of human T cells was detected in the liver
of HBV infected humanized mice compared to mock animals
(Figure 3F).
Figure 1. Murine-specific Fas antibody treatment promotes human liver reconstitution in A2/NSG-hu HSC/Hep mice. A–B: Anti-
mouse Fas (mFas) antibody enhances human hepatocyte repopulation in A2/NSG immunodeficient mice transplanted with human HSC and liver
progenitor cells. Littermate A2/NSG mice transplanted with human CD34+ HSC and hepatocyte progenitors (HSC/Hep) were treated with vehicle or
mFas activating antibody and sacrifice at 3 months post transplantation. (A) Liver sections from vehicle (PBS) or Fas antibody treated humanized mice
were stained with anti-human HepPar1 monoclonal antibody. (B) % Hep Par1+ cells per total liver cells for each mouse was quantified using 5
different fields and summarized. *, p,0.05. (C) Elevated human serum albumin levels in Jo2 (mFas Ab) treated A2/NSG-hu HSC/Hep mice compared
to pre-Jo2 (mFas Ab) treatment (n = 35, 3 cohorts). (D) Comparative analysis of human immune reconstitution (hCD45%) in A2/NSG/Fas-hu HSC/Hep
mice and A2/NSG-hu HSC mice (n = 40, 3 cohorts). (E) Human immune reconstitution of liver and lymphoid tissue (spleen) in A2/NSG/Fas-hu HSC/Hep
mice. Total leukocytes from indicated tissues were stained with human (hCD45+) and murine (mCD45+) leukocyte antibody plus dead cell marker
(Y7).
doi:10.1371/journal.ppat.1004032.g001
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Chronic HBV infection induces chronic hepatitis and
human liver fibrosis in A2/NSG/Fas-hu mice
Chronic HBV infection in patients is associated with chronic
hepatitis and liver fibrosis, characterized by leukocyte infiltration
and collagen deposition in portal/periportal regions of the liver
[38]. To examine leukocyte infiltration and fibrosis in HBV
infected liver of humanized mice, liver sections were examined at
time of sacrifice. HBV infection resulted in significant infiltration
of human leukocytes (blue cells - H&E, brown cells - hCD45+) in
the portal/periportal regions of infected livers (Figure 4A).
Hepatitis was absent in control animals (mock inoculated
humanized mice and non-transplanted mice inoculated with
HBV) (Figure 4A).
Liver fibrosis is characterized by activation of hepatic stellate
cells, which promote increased collagen deposition that results in
tissue pathology [39]. Gross morphological examination of livers
from HBV infected humanized animals also showed extensive
tissue scarring; control livers were morphologically normal (Figure
S4). Examination of liver fibrosis using Sirius red/fast green (SR/
FG) and Masson’s trichrome (MT) staining showed increased
collagen deposition in livers of HBV infected humanized mice but
not of control animals (Figure 4A, Table S1). HBV-induced liver
fibrosis was associated with elevated activation/expansion of
human hepatic stellate cells/myofibroblasts as measured by
human aSMA- and GFAP-positive cells (Figure 4A). Additionally,
human collagen 1 expression but not mouse collagen 1 expression
was unregulated in HBV-induced fibrotic liver tissues (Figure 4B,
4C).
Anti-HBs neutralizing antibody treatment prevents HBV
infection and associated liver diseases in the A2/NSG/Fas-
hu mouse model
To demonstrate that HBV is the pathogenic agent in human
HBV+ serum-induced liver disease in the A2/NSG/Fas-hu mouse
model, humanized animals were inoculated with HBV in the
presence of anti-HBsAg neutralizing antibody (NAb) (Table S1).
HBs antigens in the blood were detected in ,75% of humanized
animals inoculated with HBV alone but not in anti-HBsAg
Figure 2. Persistent HBV infection in A2/NSG/Fas-hu HSC/Hep mice. (A) A2/NSG/Fas-hu mice or non-humanized mice were inoculated with
PBS or HBV (1610e3, 10e5 or 10e7 GE/mouse). Blood samples were collected at various times after infection. HBV genomic DNA was examined in sera
from humanized mice infected with HBV at indicated titration dose and time points. (B) A2/NSG/Fas-hu mice or non-humanized mice were
inoculated with PBS or HBV (1610e6 GE/mouse). Blood samples were collected at various times after infection and HBs antigen in sera was measured
by ELISA. (C) HBV genomic DNA was detected in sera from HBV-infected humanized mice at termination time points (14–16 wpi). {: Unable to bleed
animal at later time points. (D) Liver samples were collected at termination time points (12–16 wpi). HBV core and surface antigens were detected in
livers of HBV inoculated humanized mice and not in control groups.
doi:10.1371/journal.ppat.1004032.g002
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neutralizing antibody treated or control groups (Figure 5A, Table
S1). Immunohistochemical analysis showed the presence of HBV
core and surface antigens in the liver of HBV-infected, but not in
the HBV-neutralizing antibody or mock inoculated mice
(Figure 5B, Table S1). As expected, anti-HBs neutralizing
antibody treatment also blocked HBV-induced liver diseases,
including chronic hepatitis (leukocytes, hCD45+ cells) and liver
fibrosis (MT) (Figure 5C, Table S1). Additionally, elevated levels of
serum biomarkers of liver fibrosis (gamma-glutamyl transpeptidase
- GGT and hyaluronic acid - HA) were detected in HBV infected
humanized mice compared to mock animals; neutralizing
antibody treatment blocked the induction of these serum
biomarkers (Figure 5D).
Persistent HBV infection is associated with impaired anti-
HBV human immune response in the liver
Several studies have suggested liver specific T cell immune
impairment in chronic HBV infection [5]. To characterize anti-
HBV human T cell immune response in lymphoid and liver
tissues, HLA-A2 donor derived-leukocytes from the spleen and
lymph nodes or livers of mock-, HBV plus neutralizing antibody-
or HBV-infected humanized animals were collected and stimulat-
ed/expanded in vitro with PHA or A2-restricted HBV peptides plus
anti-CD28 mAb and expanded in the presence of IL2 and IL7 for
2 weeks. Analysis of human T cell expansion following HBV
antigen stimulation showed robust expansion of human lymphoid
T cells from HBV-infected humanized mice; lymphoid T cells
from mock or HBV plus neutralizing antibody inoculated animals
exhibited refractory response to HBV antigen stimulation
(Figure 6A). Additionally, PMA plus ionomycin re-stimulation of
PHA expanded human lymphoid T cells resulted in enhanced
cytokine production (IFNc/IL2 or IFNc/TNFa double positive
cells) by T cells from HBV infected animals compared to mock or
HBV plus anti-HBs neutralizing antibody inoculated animals
(Figure 6B; Figure S5). Comparative analysis of liver and lymphoid
tissue T cell expansion following HBV antigen stimulation showed
robust expansion of lymphoid T cells from HBV-infected
humanized mice; however, liver T cells exhibited significantly
lower response compared to lymphoid T cells from the same
persistently infected animal with the exception of an HBV
Figure 3. HBV infection induces anti-HBV human immune response in A2/NSG/Fas-hu mice. HBV infection results in human immune
response with induction of serum levels of human inflammatory cytokines (A), B cells response (serum IgM and IgG antibodies levels) (B) and T cell
response (C–F). (C–F): Expansion of human T cells following stimulation with PHA or HBV antigens plus anti-CD28 mAb (14 days with IL7 and IL2) of
human lymphoid tissue T cells from mock and HBV infected mice. Total human T cell expansion for PHA (C), HBV antigen and resulting percentage of
expanded CD4+ and CD8+ T cells (D) following stimulation are presented. Error bars are shown as standard deviations. (E) HBV infection induced
HLA-A2 restricted HBV-core (18–27)- or HBV-envelope (183–191)-specific CD8+ T cells. Antigen specific CD8+ T cells were detected after expansion
with HBV antigens for 14 days as above. The immunodominant HBV-core (18–27) epitope induced higher levels of CD8+ T cells than the HBV-
envelope (183–191) epitope. Spleen cells from mock-infected mice did not respond to stimulation with HBV antigens and showed no detectable
antigen-specific T cells. (F) HBV infection and associated immune response induced liver infiltration of human T cells. Liver sections from Mock and
HBV inoculated humanized mice sacrificed at 12–16 weeks post inoculation were stained with human CD3 (human T cells, red) antibodies. No
significant leukocyte infiltration was observed in livers from mock animals.
doi:10.1371/journal.ppat.1004032.g003
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inoculated animal (#1476) that did not developed persistent
infection (Figure 6C). Both lymphoid and liver T cells from mock
and HBV plus neutralizing antibody inoculated animals exhibited
no significant response to HBV antigen stimulation (Figure 6C).
HBV-induced liver disease and immune impairment in
the liver is associated with induction of M2-like
macrophages
Several studies have indicated that macrophages play a critical
role in modulating pathogen clearance, chronic inflammation and
associated tissue pathology; with M1-like macrophages promoting
pathogen clearance, and M2-like macrophages impairing Th1
immune response and promoting tissue fibrosis/remodeling/
wound healing [40]. Immunohistochemical analysis of HBV
associated liver inflammation in humanized mice showed high
levels of human macrophages with predominately ‘‘M2-like’’
phenotype (hCD68high, hCD14high, hCD16low/medium,
hCD163high, hCD206high, hCD86negative) (Figure 7A). Additional-
ly, gene expression analysis also confirms elevated levels of human
M2 macrophages (hiNOSnegative, hIL10high, hCD163high,
hCD206high, hIL1RAhigh) (Figure 7B). Several studies have
demonstrated that M2-like macrophages are potent immune
suppressor cells expressing high levels of IL10, co-inhibitory
molecules (B7-H4), while depleting L-arginine and down-regulat-
ing IL12, TNFa and co-stimulatory molecules (CD86); all factors
critical for Th1 anti-viral immune response [41]. Analysis of liver
inflammation in HBV infected humanized mice showed human
M2 macrophages co-localized with human T cells (Figure 7C,
Table S2). Additionally, liver analysis of HBV inoculated
humanized animals that did not develop persistent infection
(ID# 1450 and ID# 1476), showed the absence of M2-like
macrophages was associated with the absence of persistent
infection and associated liver disease (Figure 6C, Table S2).
Interestingly, analysis of T cell response to antigen stimulation
showed similar robust induction for both lymphoid and liver T
cells (ID# 1476); this is in contrast to persistently infected animals
that exhibited robust lymphoid T cell response but relatively
refractory liver T cell response (Figure 6C, Table S2). Further-
more, analysis of Liver and spleen from the same persistently
infected animals showed M2 macrophages preferentially localized
to the liver and not the spleen; thus associating the presence of
M2-like macrophages in the liver with T cell impairment (Figure
S6). M2-like macrophages also localized with activated human
hepatic stellate cells (hGFAP+) and fibrotic regions (blue regions)
in HBV infected humanized livers (Figure 7D, Figure S7, Table
S2). These results suggest that persistent HBV infection-induced
liver disease and immune impairment in humanized mice is
associated with M2-like macrophage infiltration.
To confirm our findings in human HBV patients, patient groups
with varying degree of chronic HBV-induced liver diseases
(Fibrosis/HCC) were examined. Analysis of chronic HBV
associated liver diseases in humans showed high levels of
predominately ‘‘M2-like’’ macrophage (CD68high, CD206high) in
the liver infiltration (Figure 7E). Though chronic HBV-induced
liver disease accounts for the vast majority of HBV associated
morbidity/mortality, acute HBV infection occasionally results in
accelerated liver disease and liver failure with subsequent mortality
in the absence of liver transplantation [8]. Analysis of liver gene
expression profile in acute HBV-induced liver failure patients also
showed increased macrophage infiltration (CD68 upregulation),
up-regulation of M2-like macrophage genes (IL10RA - Interleukin
10 receptor alpha subunit, Dectin-1, CD163, CD163L1, MRC1
Figure 4. HBV infection induces chronic hepatitis and human liver fibrosis. A2/NSG/Fas-hu HSC/Hep mice were inoculated with Mock or
HBV and terminated at 12–16 weeks post infection. (A) Representative liver sections from sacrificed HBV infected or control mice stained with H&E
and hCD45 to examine human leukocyte infiltration and Sirius red/fast green (SR/FG) and Masson’s trichrome (MT) stains to examine liver fibrosis.
Human specific a-SMA (alpha-smooth muscle actin) and GFAP (glial fibrillary acidic protein) antibodies were used to detect activated human hepatic
stellate cell activation or myofibroblasts. Livers from two representative mice per group are shown. Gene expression analysis of human and mouse
collagen 1 was examined using species-specific primers (B) and antibodies (C). A black arrow denotes marking indicating same region.
doi:10.1371/journal.ppat.1004032.g004
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(CD206) - C-type mannose receptor 1, MRC2 - C-type mannose
receptor 2, AMAC1 - alternative macrophage activation-associat-
ed CC chemokine-1, IL10, B7-H4) and down-regulation or no
change of M1-like macrophage genes (TNFa, iNOS, IL12p40) in
HBV infected patients compared to healthy controls (Figure S8,
S9) [8,9]. Furthermore, liver gene expression profile analysis
showed M2-like macrophage gene expression profile (CD68high,
CD163high, AMAC1high, iNOSlow, TNFalow) is associated with
upregulation of tissue fibrosis (COL1A1high, TIMP1high) and
damage markers (HMGB1high [42,43,44], S100A9high [45,46])
(Figure S9) [8,9].
Results from several cell culture studies have suggested that
HBV can modulate monocyte activation resulting in induction of
M2 associated cytokines and inhibition of M1 associated cytokines
[20,22,47,48,49]. Here we demonstrate that HBV viral stock
promoted M2-like macrophage activation in both human M1 and
M2 polarized macrophages as examined by the induction of
spindle/fibroblast shaped morphology (as opposed to round/oval
shaped morphology of M1 macrophages) and M2 associated gene
expression (AMAC1high, CD86low) (Figure 8A, 8B). Additionally,
HBV inoculation resulted in induction of M2-like cytokine
markers (IL10high and IL12low) in both M1 and M2 polarized
macrophages (Figure 8C). Activation of M1 and M2 polarized
macrophages with activating cytokines results in enhanced
polarization/activation of the respective lineage. Interestingly
inoculation of M1 and M2 activated macrophages with HBV also
resulted in the induction of IL10 and the inhibition of IL12
secretion (Figure 8C). Together these results suggest that HBV
promotes M2-like macrophage activation to impair Th1 immune
response and promote liver fibrosis/pathology.
Discussion
We report here a humanized mouse model engrafted with both
human immune cells and liver cells. The A2/NSG/Fas-hu HSC/
Hep mouse supported persistent HBV infection, which induced
human immune response, albeit impaired in the liver, chronic
hepatitis and liver fibrosis. Therefore, the A2/NSG/Fas-hu mouse
provides a novel humanized mouse model with both human
immune and liver cells for studying hepatotropic pathogen
infection and associated liver diseases. More importantly, this
humanized mouse model strategy can be readily applied across
Figure 5. Anti-HBs neutralizing antibody prevents HBV infection and associated liver diseases. A2/NSG/Fas-hu HSC/Hep mice were
inoculated with HBV +/2 anti-HBs neutralizing antibody (NAb) terminated at 10–16 week post infection. (A) Serum level of HBs antigen was
measured at sacrifice time point in mock, HBV alone or HBV + anti-HBs antibody groups. (B) Liver sections from mock, HBV or HBV plus anti-HBs
antibody treated animals (representative two mice per group) were stained for HBV core or surface antigens. (C) Representative liver sections from
mock, HBV or HBV plus anti-HBs antibody treated animals were stained with H&E and hCD45 to examine human leukocyte infiltration and Masson’s
trichrome (MT) stains to examine liver fibrosis. (D) Liver fibrosis was also examined using serum biomarkers (GGT and HA) in mock (n = 6), HBV (n = 7)
or HBV plus anti-HBs antibody treated (n = 3) animals.
doi:10.1371/journal.ppat.1004032.g005
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current and future immunodeficient mouse models to promote
both human liver and immune cells repopulation.
Immunodeficient mice expressing the uPA transgene in the liver
of SCID mice or with mutant Fah genes allow transplanted human
adult hepatocytes to have a growth advantage and efficiently
repopulate the liver [50]. However, these mice have disadvantages
including neonatal death, poor health and, most importantly, the
lack of a human immune system [19]. To overcome these
deficiencies, the A2/NSG/Fas-humanized mouse model enables
inducible depletion of murine hepatocytes through the Fas
apoptotic signaling pathway, resulting in elevated human liver
repopulation in mice transplanted with human liver progenitor
and hematopoietic stem cells [32,33,34,36,51]. Additionally, the
A2/NSG background permits highly efficient engraftment and
development of human xenografts including human hematopoietic
stem cells compared to current immunodeficient mouse models
[52]. Lower levels of human hepatocytes were detected in A2/
NSG/Fas-humanized mice in comparison to the uPA or FAH
mice transplanted with adult human hepatocytes. However, it
should be noted that fetal liver cell repopulation is also low in those
mouse models [53]. Genetic modification of human liver cells for
enhanced survival, repopulation and differentiation coupled with
mouse Fas agonist (Jo2) [34] and/or the AFC8 murine liver
damage system [18] could further enhance human liver
repopulation.
To examine the applicability of the A2/NSG/Fas-humanized
mouse model for HBV infection studies, we inoculated humanized
animals with clinical HBV isolates. We detected persistent HBV
surface antigens and HBV genome in the sera of inoculated
animals. Additionally, HBV core and surface antigens were
detected in the livers of inoculated mice over 3–4 months after
infection, which indicate that the A2/NSG/Fas-humanized mouse
Figure 6. Persistent HBV infection is associated with liver specific immune impairment. Expansion of human T cells following stimulation
with PHA or HBV antigens plus anti-CD28 mAb (14 days with IL7 and IL2) of human T cells from liver or lymphoid tissues of mock, HBV plus
neutralizing antibody or HBV infected mice. (A) Total human T cell expansion after 2 weeks of stimulation with HBV antigen was examined. (B) Th1
associated double positive cytokine production in PHA expanded T cells re-stimulated with PMA plus ionomycin was also examined. (C) Comparative
analysis of HBsAg level in individual animals (Mock, PBS inoculated; HBV+, HBV inoculated with persistent HBV infection; HBV2, HBV inoculated with
no infection; +NAb, HBV plus anti-HBsAg neutralizing antibody inoculated), and associated human liver and lymphoid tissue T cell expansion
following HBV antigen stimulation. NA (Not applicable, indicating animals with low number of T cells in the liver below the assay requirements, thus
not tested). ND (Not detectable).
doi:10.1371/journal.ppat.1004032.g006
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model supports persistent HBV infection. Importantly, treatment
with anti-HBs neutralizing antibodies prevented HBV infection in
the A2/NSG/Fas-hu mouse model. The A2/NSG/Fas-hu HSC/
Hep mouse model enabled the development of human immune
cells in the blood, lymphoid tissues and the liver, thus anti-HBV
immune response was examined. Ex vivo T cell activation analysis
showed that human lymphoid T cells from HBV infected
humanized mice exhibited robust expansion in response to HBV
antigen stimulation. Furthermore, elevated human anti-viral
cytokines were detected in HBV infected humanized mice. Robust
anti-HBV B cell response is very critical for vaccine associated
prevention of HBV infection. However, only suboptimal B cell
response has been reported thus far in humanized mouse models
[52]. In concordance with those studies, we detected predom-
inantly human IgM antibodies with anti-HBV activity in HBV
infected animals. Although human lymphoid T cells exhibited
robust anti-HBV immune responses, HBV infection resulted in
persistent infection in approximately 75% of inoculated animals,
which was associated with liver specific T cell impairment. The
low HBV viremia in the blood of HBV-inoculated humanized
mice may be due to the relatively low level of human hepatocyte
engraftment (,20%) and the immature human hepatocytes
derived from fetal liver progenitor cells. Additionally, the anti-
HBV immune response could also contribute to the low viremia.
In chronically infected patients, immune and inflammatory
responses against HBV are implicated as the major mediators of
liver diseases [54,55]. Chronic HBV infection in the liver of A2/
NSG/Fas-hu mice was associated with significant human leuko-
cyte infiltration, leading to human hepatic stellate cell activation
and human liver fibrosis. Several reports have shown macrophage
activation/polarization plays a critical role in modulating patho-
gen clearance, chronic inflammation and associated tissue fibrosis
and damage; with M1 polarized macrophages promoting anti-
virus Th1 immune response and pathogen clearance, while
M2 polarized macrophages impair Th1 immune response
and promoting tissue remodeling [23,24,25,26,27]. M2 macro-
phages are critical innate immune cells involved in tissue
remodeling/wound repair, secreting anti-inflammatory cytokines
Figure 7. HBV-induced liver disease and immune impairment is associated with M2-like macrophage activation. A2/NSG/Fas-hu HSC/
Hep mice were infected with Mock or HBV and terminated at 12–16 weeks post infection. (A) Infiltrating monocyte/macrophage (CD68+, CD14high,
CD16low/medium) from HBV-infected and control livers were stained for M1-like marker (CD86+) and M2-like markers (CD163+, CD206+). (B) Elevated
levels of human M2-like macrophage gene expression profile in HBV infected humanized livers. (C–D) HBV-induced M2-like macrophage co-localized
with human T cells (C), activated hepatic stellate cells and fibrotic regions (D) in infected humanized livers. (E) Sex and age matched control and
chronic HBV patients at varying stages of liver diseases were examined to characterize macrophages (CD68+) in chronic HBV infection. Representative
M2-like marker (CD206+) and fibrosis (Sirius red) were stained in healthy controls and chronic HBV-infected human livers. CHB, Chronic HBV infection;
G1S1/G1S3, stage 1/stage 3; LC, chronic HBV associated hepatocyte cell carcinoma. Chronic HBV-induced fibrotic (CHB) and liver cancer (LC) patients
exhibited elevated levels of macrophages (CD68+) of M2-like lineage (CD206+) in the liver. A black arrow denotes marking indicating same region.
doi:10.1371/journal.ppat.1004032.g007
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and redistributing micronutrients to sites of wound repair;
however, during chronic infection, M2-like macrophages promote
tissue fibrosis, neoplasia and impair Th1 response thus promoting
pathogen persistence and associated tissue pathology [40]. We
report that liver inflammation and immune impairment in chronic
HBV infected humanized mice livers was associated with M2-like
macrophages, which also localized to fibrotic regions. Most
importantly, results from chronic HBV and acute HBV-induced
liver disease/failure patients confirmed that accumulation of M2-
like macrophages correlated with liver disease progression and
failure. Several studies have reported that HBV virus/HBV-
encoded proteins can directly promote M2-like activation
[20,21,22]. We confirmed and extended those results by demon-
strating that HBV promotes M2 macrophage polarization in
human M1 and M2 macrophages.
In summary, we have established a novel humanized mouse
model with both human liver cells and immune system (A2/NSG/
Fas-hu HSC/Hep mice) using a highly immunodeficient mouse
strain that efficiently supports human cell engraftment. A2/NSG/
Fas-hu HSC/Hep mice were susceptible to chronic HBV infection,
associated with HBV-specific human immune responses and liver
immune impairment, chronic inflammation and fibrosis. Important-
ly, our findings suggest a critical role for M2-like macrophages in
HBV infection, immune dysregulation and associated liver diseases.
Materials and Methods
Ethics statement
All animal experiments were conducted following NIH guide-
lines for housing and care of laboratory animals and in accordance
with The University of North Carolina at Chapel Hill in
accordance with protocols approved by the institution’s Institu-
tional Animal Care and Use Committee (protocol number 10-
107). Human study protocols were approved by Beijing 302
Hospital Research and Ethics Committee and the independent
ethics committee (IEC) of Jilin University; written informed
consent was obtained from all participants. Liver gene expression
profile analyses in patients were obtained from a dataset in Gene
Expression Omnibus (GEO)/NCBI database; the reports followed
NIH research ethics guidelines [8,9].
Isolation of CD34+ HSC and liver progenitor cells from
human fetal liver
Human liver progenitor cells containing hepatoblasts (Hep) and
CD34+ hematopoietic stem cells (HSC) were isolated from 15–19
weeks old human fetal liver tissue (Advanced Bioscience Resourc-
es) essentially as described [56,57,58]. To separate progenitor liver
cells from non-parenchymal cells (including HSC), the fetal liver
cells were centrifuged at low speed three times (5 minutes, 186g).
Figure 8. HBV induces M2-like activation in human macrophages. (A–B) Polarized M1 or M2 monocyte-derived macrophages were treated
with HBV (HepG2.2.15 derived), or mock (HepG2 derived) for 6 days and M1 and M2 macrophage activation was examined using (A) morphological
analysis (oval/round shape – M1, spindle/fibroblast shape – M2) and (B) gene expression analysis (CD86 – M1, AMAC1 – M2). (C) Polarized or activated
(enhanced polarization) M1 or M2 monocyte-derieved macrophages were treated with HBV (HepG2.2.15 derived), or mock (HepG2 derived) for 6 days
and M1 and M2 macrophage activation was examined using cytokine analysis (IL12 – M1, IL10 – M2).
doi:10.1371/journal.ppat.1004032.g008
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Liver progenitor cells were collected in the pellet. The supernatant
was centrifuged at 4696g for 5 min to collect the non-parenchyma
mononuclear cells. CD34+ cells were isolated by magnetic-
activated cell sorting (MACS), and the purity of CD34+ HSCs
was greater than 95%. Cell viability, measured using Guava
Easycyte -with Viacount staining (Millipore), generally exceeded
90%.
Construction of A2/NSG/Fas-hu mice with human
immune and liver cells
CD34+ HSCs (0.5–16106) and Hep (liver) progenitor cells (0.5–
16106) from the same donor liver were co-injected into the liver of
1 to 2 days old newborn A2/NSG mice, previously irradiated at
200 rad. Additionally, fetal thymus tissue from the same donor was
also transplanted when available. Animals were injected 3–5 times
via ip with Jo2 antibody/PBS at 0.1–0.15 mg/kg body weight (BD
Pharmingen) every 4–5 days at approximately 3–4 weeks post
transplant of human cells [59]. At 12–16 weeks post-transplant
with HSC+Hep cells, Transplanted mice were bled to determine
human leukocyte (hCD45+) reconstitution by FACS and human
albumin concentration in the blood by ELISA (Bethyl laborato-
ries). All experiments using live rodents conformed to governmen-
tal and institutional guidelines.
HBV infection of humanized mice
HBV clinical isolates were obtained from patients with chronic
HBV infection (patient # 1 – HBV #1 and patient # 2 – HBV
#2). A2/NSG-humanized mice or non-humanized control mice
were inoculated iv with 50–75 ul of clinical isolates of HBV
(16103–16107 genome equivalent copies) plus or minus anti-
HBsAg ScFv neutralizing antibody (NAb) mixture (40 ug) per
mouse or vehicle control (PBS). For in vivo neutralization assay,
virus plus or minus monoclonal antibodies mixture was
incubated at 25 degrees (room temperature) for 1 hour prior to
inoculation.
Blood and tissue analysis of A2/NSG/Fas-humanized mice
At different times after infection, blood was collected and
HBsAg levels were measured using in house ELISA consisting of
anti-HBsAg ScFv monoclonal antibodies mixture and commercial
reagents (Alpha Diagnostics). HBV serum genome was detected at
termination using real-time PCR [60]. Serum cytokine levels were
measure using a multiplex human cytokine array and following
manufacturer’s recommended procedures (Luminex, Millipore).
Liver fibrosis serum biomarkers, gamma-glutamyl transpeptidase
(GGT) was measure using MaxDiscovery GGT enzymatic assay
(Bioo Scientific Corporation) and hyaluronic acid (HA) was
measured using hyaluronic acid ELISA kit (Echelon Biosciences)
were measure following manufacturer’s recommended procedures.
At termination, liver tissue was immediately place in RNAlater
(Qiagen) or fixed in 10% formalin. RNAlater was removed from
tissue and samples were stored in 280 C. RNA was isolated from
tissue following manufacturer’s recommended procedures and
qPCR was performed using species-specific published [18,61] or
NCBI primer blast generated primers and the SYBR Green
method, following manufacturer’s recommended procedures
(Thermo Scientific). Paraffin embedded fixed liver sections were
stained with hematoxylin and eosin (H&E), sirius red/fast green
(fibrosis), Masson’s trichrome (fibrosis) or with antibodies: anti-
human GFAP (1:250; Abcam), anti-human Collagen 1 (1:250;
Abcam), anti-mouse Collagen 1 (1:250; Abcam), anti-human a-
smooth muscle actin (1:75; Dako), anti-human CD45 (1:2, Dako),
anti-human CD3 (1:250; Dako), anti-human CD68 (1:250; Dako),
anti-human albumin (1:250; Dako), anti-Hep Par1 (Dako), anti-
HBcAg (1:100; Zeta Corp). anti-HBsAg (1:100; Thermo Scientif-
ic). Immunoreactivity was determined by incubation with DAB
substrate (Pierce) or Vulcan red (Dako), and counterstained with
hematoxilin [56,58]. Liver histological activity was determined
using the knodell score, which examines liver necrosis, degener-
ation, inflammation and fibrosis [62,63].
T cell immune responses in mock or HBV-infected A2/
NSG/Fas-hu mice
Spleens, mesenteric lymph nodes and liver were isolated from
individual animals and 0.56106 human spleen plus mesenteric
lymph node or liver leukocytes were stimulated for 20 hours with
phytohemagglutinin (PHA) or HBV antigens [HLA2 core (18–27),
envelope (183–191, 185–194, 172–181), polymerase (573–581)
peptides (ProImmune) +/2 recombinant HBc and HBs (ProSpec)
at 10 ug/ml each]+1 ug/ml anti-CD28 mAb (Invitrogen) in
IMDM+10% FBS media (Gibco). The cells were then cultured
for 14 days with fresh media replaced every two days (IMDM,
10% FBS, 10 U/mL human IL-2 and 125 ng/mL IL-7; human T
cell expansion was examined by FACs (Guava, Millipore) using
CD45, CD3 and live cell marker. Additionally, cells were stain for
HBV core (18–27) or HBV envelope (183–191) pentamer+ human
CD8+ T cells (ProImmune). PHA expanded cells were re-
stimulated with Phorbol 12-myristate 13-acetate (PMA) plus
ionomycin for approximately 6 hours and cytokine secretion was
block with brefeldin A; intracellular cytokine levels were examined
using FACs.
Human patient samples and analyses
Chronic HBV Infection and associated liver diseases: Fifty-two
chronic HBV (CHB) patients and 22 liver cancer (LC) patients
were recruited for this study. All patients were diagnosed
according to our previously described criteria [64,65] and had
not received any antiviral therapies or immunosuppressive drugs
within six months before sampling. Sixteen age- and sex-matched
healthy individuals were enrolled as controls (HC). Individuals
with concurrent HCV, HDV or HIV infections, autoimmune liver
diseases or alcoholic liver disease were excluded.
Acute HBV - induced accelerated liver disease and failure:
Gene expression analysis was performed on publicly available
microarray dataset from patients with acute HBV-associated liver
failure (n = 4 patients, 17 different liver specimens approximately
evenly taken from the 4 livers) and match healthy control liver
donors (n = 10); acute HBV- induced liver failure patients were
previously healthy and had no signs of chronic liver disease [8].
Microarray dataset (GEO accession: GSE49656; [8]) was analyzed
using GEOR (NCBI Software).
Human macrophage culture
PBMC were isolated from the buffy coats of healthy HIV-1/
HBV/HCV sero/qPCR negative blood donors by Ficoll-paque
density gradient centrifugation. The cells were then washed,
resuspended in RPMI containing pen/strep (1%), glutamine (1%),
heat-inactivated FBS (10%), and seeded into tissue culture plates.
Non-adherent cells, mostly T lymphocytes, were removed by
gentle pipette aspiration after 1.5 h of incubation at 37uC in a
humidified atmosphere containing 5% CO2. An equal volume of
fresh complete medium was then added to each flask and attached
cells at approximately 70–80% confluency were cultivated for 6
additional days at 37uC in 5% CO2 in presence of either rHuGM-
CSF (100 ng/ml) (M1) or rHuM-CSF (100 ng/ml) (M2) for
differentiation into polarized M1 or M2 - monocyte derived
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macrophages. These polarized macrophages ($95% CD14+) were
then stimulated for two days with either IFN-c (50 ng/ml) and
LPS (10 ng/ml) or IL-4 (20 ng/ml) to obtain activated M1
macrophages or activated M2 macrophages, respectively. Polar-
ized or activated primary monocyte derived macrophages were
washed and treated with medium containing HBV (HBV positive
HepG2 cell line - HepG2.2.15 supernatant derived at MOI = 10)
or Mock (HBV negative HepG2 cell line - HepG2 supernatant
derived) for 6 days; M1 and M2 macrophage activation were
examined using cytokine analysis (BD Biosciences) and qPCR
(Invitrogen) following manufactures’ recommended procedures.
Statistical analysis
We used unpaired two-tailed Student’s t-tests or ANOVA for all
comparisons. p,0.05 is considered significant. All data are
reported as means 6 standard error.
Supporting Information
Figure S1 Anti-mouse Fas activating antibody exhibits
murine-specific affinity and hepatotoxicity. (A) Human
hepatocyte cell line (HepG2) was culture in DMEM based complete
medium and stained with PE-conjugated anti-human CD95
antibody (clone DX2, eBioscience) or PE-conjugated anti-mouse
CD95 antibody (Jo2 antibody) (BD Pharmingen) and analyzed by
FACs; Jo2 exhibits species-specific affinity for murine CD95. (B)
Human fetal liver progenitor cells (7e5 cells per well) were cultured
in 12 well plates and treated with Jo2 (500 ng/mL) or vehicle (PBS)
for 3 days and cell death was examined using both FACs based
viability staining assay. Treatment of fetal liver progenitor cells
culture with Jo2 does not induce apoptosis. (n = 3 per treatment
group) (C) For studies examining Fas activating antibody in vivo
hepatotoxic activity, A2/NSG immunodeficient mice were injected
once via ip with Jo2 at sub-lethal doses or vehicle (PBS) and ALT
levels was measure 20 hours post treatment. Jo2 induces dose
dependent murine liver damage in A2/NSG immunodeficient mice
(n = 2 per treatment group). p,0.05 is considered significant. All
data are reported as means 6 standard error.
(PDF)
Figure S2 Human immune reconstitution in A2/NSG/
HSC-Hep Fas mice. Leukocytes from indicated tissue were
isolated and stain for various human immune lineages including T
cells (hCD45+ hCD3+), B cells (hCD45+ hCD19+), monocytes/
macrophages (hCD45+ hCD32 hCD192 hCD562 hHLADR+
hCD14high hCD11Chigh), myeloid dendritic cells (hCD45+
hCD32 hCD192 hCD562 hHLADR+ hCD14low hCD11Chigh)
and plasmacytoid dendritic cells (hCD45+ hCD32 hCD192
hCD562 hHLADR+ hCD123high hCD4high).
(PDF)
Figure S3 HBV genome in the liver of humanized mice.
Extrachromosomal DNA was isolated from liver samples, and
HBV DNA was quantified in mock (lanes 1–3) or HBV infected
(lanes 4–8) humanized mice using real-time PCR (A) and gel
electrophoresis analysis (B). HBV plasmid DNA from hydrody-
namically transfected mice was used as positive control of qPCR
and gel analysis (data not shown).
(PDF)
Figure S4 HBV infection induces liver fibrosis/scarring
in humanized mice. Representative gross liver morphology of
HBV-infected and mock-infected mice. HBV infection of
humanized animals was associated with gross liver pathology with
prominent scarring visible on the tissue.
(PDF)
Figure S5 HBV infection primes human T cells in
humanized mice. Representative FACs analysis of Th1
associated double positive cytokine secretion in vehicle or PMA
plus ionomycin re-stimulated PHA expanded T cells.
(PDF)
Figure S6 Liver specific localization of human M2-like
macrophages in HBV infected humanized mice. Immu-
nohistochemical analysis of M2 macrophage (CD68+,
CD163+) levels in the spleen and liver of the same HBV-
infected animal. Black arrows serve as a marker to denote the
same region.
(PDF)
Figure S7 Chronic HBV infection–induced liver fibrosis
is associated with M2-like macrophages in humanized
mice. (A–B) Livers from representative HBV infected humanized
mice (HBV), mock (Mock) inoculated humanized mice and HBV
inoculated non-humanized (NTP-HBV) control mice were stained
for M2-like (CD163+, brown regions) macrophages and liver
fibrosis (MT, blue regions) and slides were scanned (A);
additionally an enlarged HBV infected liver is shown (B), black
arrows serve as a marker to denote the same region. (C)
Quantitative analysis of CD163+ macrophages (brown color)
and liver fibrosis (collagen deposition-blue color) in the indicated
livers.
(PDF)
Figure S8 Acute HBV infection–induced accelerated
liver fibrosis and damage is associated with the
induction of M2-like macrophage gene expression
profile in humans. Relative log2 expression of macrophage
(CD68), M2-like macrophage (IL10RA, Dectin-1, CD163,
CD163L1, MRC1(CD206), MRC2, AMAC1, IL10, B7-H4) and
M1-like macrophage (TNFa, iNOS, IL12p40) markers in the
livers of healthy control liver donors (n = 10) and human patients
with acute HBV – induced liver failure (n = 17 from 4 patients).
(PDF)
Figure S9 M2-like macrophage gene expression profile
directly correlates with liver fibrosis and damage
markers in Acute-HBV liver failure patients. Regression/
correlation analysis of relative log2 expression (RE) of macrophage
(CD68) marker and M2-like macrophage (CD163, AMAC1) or
M1-like macrophage (TNFa, iNOS) markers in the livers of
human patients with acute HBV – induced liver failure show
elevated levels of M2-like macrophage directly correlate with
macrophage levels. Additionally, regression/correlation analysis of
relative log2 expression of M2-like macrophage (CD163) marker
and tissue fibrosis (COL1A1, TIMP1) or damage (HMGB1,
S100A9) markers show M2-like macrophage levels correlate with
liver fibrosis and damage levels.
(PDF)
Table S1 Chronic HBV infection induces liver disease in
the humanized mouse model. Animal information and
associated human reconstitution level, infection status, and liver
disease score.
(PDF)
Table S2 Chronic HBV–induced liver disease and
immune impairment is associated with M2-like macro-
phages in the humanized mouse model. Animal informa-
tion, human reconstitution status, infection status, lymphoid and
liver immune response, liver disease stage/score and associated
liver M2-like macrophage levels.
(PDF)
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